PRX and cancer: We propose that ROS modification of the expression of numerous signaling genes is also an explanation on ROS signaling, supported by (1) thousands of DEGs indicated not only by global mRNA sequencing data but also by the reduced expression of key genes in multiple signaling pathways including ERK, PI3K, and NF-κB inside the LD100-treated and SOD1 knockdown cancer cells (Figures 1 and 2), (2) the ROS signaling network that is not modified in the LD100-treated normal cells, and (3) downregulation in the cancer cells of few PRX isoforms and upregulation of few PRX isoforms in the normal cells.